Wockhardt aims Biovac B shot at regulated markets
Pharma major Wockhardt Ltd is planning to enter the regulated markets with its recombinant hepatitis-B vaccine, Biovac B, once the patent expires in 2004. Wockhardt currently sells the vaccine in
Pharma major Wockhardt Ltd is planning to enter the regulated markets with its recombinant hepatitis-B vaccine, Biovac B, once the patent expires in 2004. Wockhardt currently sells the vaccine in